Ansbert Gadicke's Net Worth

$1.04 Billion

Who is Ansbert Gadicke?

Ansbert Gadicke has an estimated net worth of $1.04 Billion. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., EnteroMedics Inc, iTeos Therapeutics, Inc., ARYx Therapeutics, Inc., PEPLIN INC, Restore Medical, Inc., CRYOCOR INC, VIACELL INC, HEMOSENSE INC, COTHERIX INC, Omrix Biopharmaceuticals, Inc., TERCICA INC, BARRIER THERAPEUTICS INC, TriVascular Technologies, Inc., RIGEL PHARMACEUTICALS INC, Cullinan Oncology, Inc., Radius Health, Inc., Entrada Therapeutics, Inc., Repare Therapeutics Inc., Dyne Therapeutics, Inc., Allovir, Inc., Verastem, Inc., Syndax Pharmaceuticals Inc, PHARMATHENE, INC, AVEO PHARMACEUTICALS INC, Pacira Pharmaceuticals, Inc., XCYTE THERAPIES INC, PONIARD PHARMACEUTICALS, INC., Harpoon Therapeutics, Inc., ACORDA THERAPEUTICS INC, ARATANA THERAPEUTICS, INC., KALOBIOS PHARMACEUTICALS INC, TCR2 THERAPEUTICS INC., Conatus Pharmaceuticals Inc, Epizyme, Inc., Werewolf Therapeutics, Inc., Cerecor Inc., Oncorus, Inc., CRITICAL THERAPEUTICS INC, Pharmasset Inc, Zalicus Inc., AFFYMAX INC, CHIASMA, INC, Somaxon Pharmaceuticals, Inc., IDENIX PHARMACEUTICALS INC, HELICOS BIOSCIENCES CORP, SENORX INC, OSCIENT PHARMACEUTICALS CORP, Alsius Corp, MEMORY PHARMACEUTICALS CORP, and METABASIS THERAPEUTICS INC.

SEC CIK

Ansbert Gadicke's CIK is 0001134655

Past Insider Trading and Trends

2020 was Ansbert Gadicke's most active year for acquiring shares with 41 total transactions. Ansbert Gadicke's most active month to acquire stocks was the month of January. 2021 was Ansbert Gadicke's most active year for disposing of shares, totalling 234 transactions. Ansbert Gadicke's most active month to dispose stocks was the month of May. 2019 saw Ansbert Gadicke paying a total of $27,627,508.38 for 15,328,700 shares, this is the most they've acquired in one year. In 2007 Ansbert Gadicke cashed out on 44,342,084 shares for a total of $97,991,841.52, their largest year based on trade value.